Skip to main content

Table 5 Patient characteristics during the intensive care unit stay

From: Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study

Ā 

Intention to treat

Modified intention to treat

Ā 

Antibiotic treatment

n = 22

No antibiotic treatment

n = 36

P value

Antibiotic treatment

n = 18

No antibiotic treatment

n = 26

P value

Tracheostomy

5 (22)

5 (13)

>0.999

5 (27)

5 (19)

0.716

Corticosteroid use

8 (36)

19 (52)

0.283

6 (33)

13 (50)

0.359

Septic shock

1 (4)

7 (19)

0.134

1 (5)

5 (19)

0.375

ICU-acquired infections other than VAT and VAPa

7 (31)

18 (50)

0.274

6 (33)

13 (50)

0.359

ā€ƒā€ƒā€ƒBacteremia

6 (27)

13 (36)

0.572

5 (27)

8 (30)

>0.999

ā€ƒā€ƒā€ƒUrinary tract infection

2 (9)

5 (13)

0.698

2 (11)

5 (19)

0.682

ā€ƒā€ƒā€ƒOthers

2 (9)

2 (5)

>0.999

2 (11)

2 (7)

>0.999

Total duration of antibiotic treatment, days

25 Ā± 14

19 Ā± 15

0.149

24 Ā± 15

17 Ā± 15

0.104

Antibiotic treatment before VAT

18 (81)

29 (80)

>0.999

15 (83)

23 (88)

0.676

Antibiotic treatment during the 8 days following random assignment

22 (100)

21 (58)

<0.001

18 (100)

10 (38)

<0.001

Reasons for antibiotic treatment during the 8 days following random assignment

Ā Ā Ā Ā Ā Ā 

ā€ƒā€ƒā€ƒVAT

22 (100)

0 (0)

<0.001

18 (100)

0 (0)

<0.001

ā€ƒā€ƒā€ƒVAP

0 (0)

15 (41)

<0.001

0 (0)

10 (38)

0.003

ā€ƒā€ƒā€ƒOther infections

0 (0)

6 (16)

0.073

0 (0)

0 (0)

NA

Antibiotic treatment after day 8 post-random assignment

6 (27)

8 (22)

0.756

3 (16)

5 (19)

>0.999

  1. Results of univariate analysis are presented. Data are expressed as frequency (percentage) or mean Ā± standard deviation. aSome patients had more than one ICU-acquired infection. ICU, intensive care unit; NA, not applicable; VAP, ventilator-associated pneumonia; VAT, ventilator-associated tracheobronchitis.